Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight…
Continue reading...